WO2006087238A9 - Method for the production of macrolides - Google Patents
Method for the production of macrolidesInfo
- Publication number
- WO2006087238A9 WO2006087238A9 PCT/EP2006/001673 EP2006001673W WO2006087238A9 WO 2006087238 A9 WO2006087238 A9 WO 2006087238A9 EP 2006001673 W EP2006001673 W EP 2006001673W WO 2006087238 A9 WO2006087238 A9 WO 2006087238A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- macrolide
- group
- agent
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Definitions
- the invention provides a process for the conversion of 6-11 bridged macrolide (e.g. erythromycin or derivatives thereof) oximes to a corresponding macrolide having corresponding keto functionality.
- 6-11 bridged macrolide e.g. erythromycin or derivatives thereof
- Ketolides and erythromycin derivatives are useful in treatment and prevention of bacterial infections.
- 6-11 Bridged bicyclic ketolides and erythromycins have been described in several publications by Enanta Pharmaceuticals Inc. The 6-11 bridge structure has been Introduced into erythromycin structures (WO 03/095466 A1, US 2004/005861 A1), ketolides with a C 3 ketone substituted for the cladinose sugar (WO 03/097659 A1, US 2004/0157787 A1, US 2004/0171818 A1, Org. Lett. 2004, 6, 4455- 4458), as well as the ring-enlarged azalides (US 6,645,941 B1, US 6,764,998 B1).
- the present invention relates to a method for the (selective) conversion of an oxime group in a macrolide to an oxo group, said method comprising treatment of the macrolide with a deoximating agent.
- the invention relates to a method for converting a macrolide of Formula Il to a macrolide of Formula III.
- R 1 and R 2 independently are alkyl, or taken together are alkylidene;
- R 3 is OH or alkoxy;
- R 4 is H or alkyl;
- R 5 is H or alkyl;
- R 8 is OH or alkoxy;
- Z is an acyl group (such as alkanoyl).
- the macrolide of Formula IV is converted to a macrolide of Formula V
- Formulas Ri and R 2 independently are H or alkyl, or taken together are alkyliden; R 3 is OH or alkoxy;
- R 4 is H or alkyl
- R 5 is H or alkyl
- Z is an acyl group (such as alkanoyl).
- an agent suitable for ketone-regeneration from oximes can be used, such as an oxidative deoximating agent, in particular a derivative of 2- lodoxybenzoic acid, such as IBX or Dess-Martin periodinane.
- Such a deoximating agent can be used alone, or together with an oxidizing agent, thus the method of the invention can be carried out be treatment of the macrolide with a deoximating agent, followed by treatment with an oxidizing agent
- a C 9 oxime, C 3 hydroxyl macrolide can, in a one-step procedure, be converted to the corresponding C 9 , C 3 di-ketone macrolide by treatment with both a deoximating and an oxidizing agent, or a single agent which is oxidizing deoximating agent, such as a derivative of 2-lodoxybenzoic acid, e.g. Dess-Martin periodinane (two equivalents).
- the invention also relates to novel compounds of the Formula I,
- Z represents H, acyl, alkanoyl or acetyl
- R3, R 4 , R 5 . R7 independently represent H, or Ci-C 6 alkyl
- the present invention provides an efficient method for converting 6-11 bridged bicyclic erythromycin 9-oximes of general formula (II) to 6-11 bridged bicyclic erythromycins of general Formula (III). Deoximation
- the transformation is mediated by treating a compound of the general Formula (II) with a suitable reagent for ketone-regeneration from oximes.
- a 3-0-desciadinosyl 6-1 1 bridged bicyclic erythromycin 9-oxime of Formula (IV) can be converted to the corresponding 6-11 bridged bicyclic ketolide of general Formula (V) in either one or optionally two sequential steps upon treatment with suitable reagents.
- deoximation of the C 9 oxime is accompanied by oxidation of the C 3 alcohol to a keto function.
- the substrate is treated with two equivalents of a reagent for oxidative deoximation.
- any deoximation reagent can be used for regeneration of the C 9 ketone.
- any oxidising agent can be used for the oxidation of the C 3 alcohol.
- the parent 6-11 bridged bicyclic ketolide compound (1-2) is available in only five chemical steps from erythromycin 9-ox ⁇ me.
- the present invention can be used to transform the compound (1-1 ) in one chemical step to the parent 6-11 bridged bicyclic ketolide (1-2) in a process with deoximation/oxidation followed by removal of the C-2' protecting group.
- the present methodology provides an efficient synthesis of 6-11 bridged bicyclic ketolides.
- the parent compound (1-2) can be prepared in no more than five synthetic steps from erythromycin 9-oxime.
- ketolide refers to derivatives of erythromycin A wherein the cladinose sugar has been removed and replaced by a C 3 keto function.
- azalide refers to derivatives of erythromycin A wherein the macrolactone ring has been extended to a 15-membered ring with a nitrogen atom included.
- alkyl includes straight or branched chain aliphatic hydrocarbon groups that are saturated and have 1 to 15 carbon atoms. Preferably, the alkyl group has 1-10 carbon atoms, and most preferred 1 , 2, 3, 4, 5, or 6 carbon atoms.
- the alkyl groups may be Interrupted by one or more heteroatoms, and may be substituted, such as with halogen, hydroxyl, aryl, cycloalkyl, aryloxy, or alkoxy.
- Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl.
- alkoxy stands for an -0-alkyl group.
- alkylidene refers to optionally unsaturated divalent alkyl radicals.
- acyl groups are formyl, C 1 -C 6 alk(en/yn)ylcarbonyl, arylcarbonyl, aryl-C r C 6 alk(en/yn)ylcarbonyl, cycloalkylcarbonyl, or cycloalkyl- C 1 -C 6 alk(en/yn)ylcarbonyl group.
- derivative of 2-lodoxybenzoic acid refers to 2-lodoxybenzoic acid (IBX) and derivatives thereof able to deoximate an oxime group, and includes Dess-Martin periodinane.
- Dess-Martin periodinane refers to the compound with the systematic name 1 ,1 ,1-triacetoxy-1 ,1-dihydro-1 ,2-benziodoxol-3-(1 H)-one.
- deoximation refers to the process where a carbonyl compound is regenerated from the corresponding oxime. In the case of deoximation of erythromycin 9-oxime derivatives, the carbonyl group is a ketone.
- the compound of structure (2-1 ) (500 mg, 0.59 mmol) is dissolved in dichloromethane saturated with water (12.5 ml), and Dess-Martin periodinane (254 mg, 0.59 mmcl) is added slowly. The reaction mixture is stirred at room temperature in inert atmosphere until TLC indicates full conversion of the starting material. Aqueous sodium hydroxide is added, and the product is extracted with dichloromethane. The combined organic layers are washed with water and brine, and dried (MgSO 4 ).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002598139A CA2598139A1 (en) | 2005-02-21 | 2006-02-21 | Method for the production of macrolides |
EP06723097A EP1856136A1 (en) | 2005-02-21 | 2006-02-21 | Method for the production of macrolides |
AU2006215709A AU2006215709A1 (en) | 2005-02-21 | 2006-02-21 | Method for the production of macrolides |
JP2007555553A JP2008530169A (en) | 2005-02-21 | 2006-02-21 | Macrolide production method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500262 | 2005-02-21 | ||
DKPA200500262 | 2005-02-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006087238A1 WO2006087238A1 (en) | 2006-08-24 |
WO2006087238A9 true WO2006087238A9 (en) | 2006-10-05 |
WO2006087238B1 WO2006087238B1 (en) | 2006-11-23 |
Family
ID=36499440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/001673 WO2006087238A1 (en) | 2005-02-21 | 2006-02-21 | Method for the production of macrolides |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1856136A1 (en) |
JP (1) | JP2008530169A (en) |
CN (1) | CN101124236A (en) |
AU (1) | AU2006215709A1 (en) |
CA (1) | CA2598139A1 (en) |
WO (1) | WO2006087238A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1633444A (en) * | 2002-05-13 | 2005-06-29 | 埃纳恩塔制药公司 | 6-11 bicyclic ketolide derivatives |
NZ536402A (en) * | 2002-05-13 | 2006-08-31 | Enanta Pharm Inc | 6,11 bicyclic erythromycin derivatives |
-
2006
- 2006-02-21 AU AU2006215709A patent/AU2006215709A1/en not_active Abandoned
- 2006-02-21 JP JP2007555553A patent/JP2008530169A/en active Pending
- 2006-02-21 EP EP06723097A patent/EP1856136A1/en not_active Withdrawn
- 2006-02-21 CN CNA2006800055686A patent/CN101124236A/en active Pending
- 2006-02-21 WO PCT/EP2006/001673 patent/WO2006087238A1/en active Application Filing
- 2006-02-21 CA CA002598139A patent/CA2598139A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006215709A1 (en) | 2006-08-24 |
CN101124236A (en) | 2008-02-13 |
WO2006087238B1 (en) | 2006-11-23 |
EP1856136A1 (en) | 2007-11-21 |
WO2006087238A1 (en) | 2006-08-24 |
JP2008530169A (en) | 2008-08-07 |
CA2598139A1 (en) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4795589B2 (en) | Process for producing 6-O-substituted erythromycin derivatives | |
CA2184734C (en) | 3''-desmethoxy derivatives of erythromycin and azithromycin | |
AU2001225787C1 (en) | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same | |
WATANABE et al. | CHEMICAL MODIFICATION OF ERYTHROMYCINS. IX. 1) SELECTIVE METHYLATION AT THE C-6 HYDROXYL GROUP OF ERYTHROMYCIN A OXIME DERIVATIVES AND PREPARATION OF CLARITHROMYCIN | |
JP5657834B2 (en) | Method for producing ketolide compounds | |
JP2001520234A (en) | Novel 3,6-hemiketals derived from 9a-azalides | |
HU193157B (en) | Process for preparing 4"-epi-erythromycin a and derivatives thereof | |
EP2220104A1 (en) | Process for the production of telithromycin | |
JP5908479B2 (en) | Novel process for producing 9-deoxo-9a-aza-9a-homoerythromycin A in which C-4 "of cladinose ring is modified with an epoxide group | |
WO2006087238A9 (en) | Method for the production of macrolides | |
EP0994889B1 (en) | Erythromycin a oxime solvates | |
CA2525143A1 (en) | New 3-decladinosyl 9a-n-carbamoyl and 9a-n-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a | |
EP1399458B1 (en) | An arylation method for the functionalization of o-allyl erythromycin derivatives | |
WO2004007518A1 (en) | Erythromycin a 9-o-pseudosaccharinyloxime derivatives and process for the preparation of clarithromycin using the same | |
EP1633764B1 (en) | Regioselective process for the preparation of o-alkyl macrolide and azalide derivatives | |
AU2002357482B2 (en) | Method for the production of desclarithromycin, and intermediate products | |
CN1239101A (en) | Process for synthesizing clamycin as antibiotic medicine | |
Bhatia | Strategies leading to the synthesis of a novel ketolide antibiotic | |
EP0972778A1 (en) | Erythromycin derivatives and methods for the preparation thereof | |
KR20000037127A (en) | Process for preparing erythromycin A 6-methyl derivatives | |
KR20010008496A (en) | Process for the preparation of 6-O-methyl erythromycin | |
KR19990085779A (en) | Method for preparing 6-0-methyl erythromycin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006723097 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006215709 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6064/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007555553 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2598139 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680005568.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
ENP | Entry into the national phase in: |
Ref document number: 2006215709 Country of ref document: AU Date of ref document: 20060221 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006215709 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006723097 Country of ref document: EP |